Annales medico-psychologiques最新文献

{"title":"Les interventions psychologiques dans la prise en charge du TDAH chez l’adulte","authors":"Maëva Roulin ,&nbsp;François Radiguer ,&nbsp;Sébastien Henrard ,&nbsp;Johanna Guinet ,&nbsp;Sophie Bayard","doi":"10.1016/j.amp.2024.06.010","DOIUrl":"10.1016/j.amp.2024.06.010","url":null,"abstract":"<div><div>Managing difficulties for people suffering from attention deficit hyperactivity disorder (ADHD) is a complex task that goes beyond the application of pharmacotherapy alone. Although stimulant medications are frequently used to treat the core symptoms of ADHD, they are not always sufficient to manage other important aspects of this disorder. The aim of this study is to complete the systematic review carried out in 2017 by the Cochrane Database of Systematic Reviews concerning psychological approaches to ADHD. To do this, we analyzed data published since 2017 in PubMed, Embase, PsycInfo and MEDLINE databases. We grouped our data by type of approach to highlight the most effective therapies for improving behavioral and functional symptoms associated with ADHD. The data collected highlights that cognitive-behavioral therapy (CBT), mindfulness-based cognitive therapy (MBCT) and psychoeducation are particularly effective, providing short-term benefits by reducing ADHD symptoms and improving associated disorders such as depression and anxiety. We conclude that there is significant evidence to support the use of specific psychological approaches in the management of ADHD in adults. Future research should examine more rigorously the lack of methodology and further integrate transdiagnostic approaches to psychopathology.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 301-307"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidités et diagnostics différentiels du Trouble Déficit de l’Attention Hyperactivité (TDAH) en fonction de l’âge","authors":"Diane Purper-Ouakil ,&nbsp;Sébastien Weibel","doi":"10.1016/j.amp.2024.09.006","DOIUrl":"10.1016/j.amp.2024.09.006","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Attention Deficit Hyperactivity Disorder (ADHD) is associated with neurodevelopmental and psychiatric comorbidities throughout life, with a profile of co-occurring disorders that tend to become more complex over time. This article synthesizes the main comorbidities and differential diagnoses of ADHD to provide guidance and facilitate the diagnostic and therapeutic process. In adolescents and adults, it is common for ADHD symptoms to be difficult to spot amid substance abuse disorders or mood disorders. However, diagnosing ADHD is crucial because its treatment can decisively improve social functioning and prognosis for individuals with comorbidities. Most comorbid disorders also serve as differential diagnoses for ADHD, with several symptoms that can be shared across multiple diagnostic categories. This is the case with difficulties in concentration, impulsivity, and irritability, for example. Comorbidities of ADHD in children and adolescents include neurodevelopmental disorders such as autism spectrum disorder (ASD), intellectual developmental disorder (IDD), communication disorders, specific learning disorders, and motor development disorders. A meta-analysis found a lifetime prevalence of ADHD in ASD to be 40,2%, and in children with ADHD, a co-occurrent diagnosis of ASD is found in 20 to 30% &lt;span&gt;&lt;span&gt;[1]&lt;/span&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;[2]&lt;/span&gt;&lt;/span&gt;. The diagnostic process can be delayed in people with both ADHD and ASD. While treatment of ADHD has documented efficacy in this population, a slow titration is recommended to minimise the risk of side effects &lt;span&gt;&lt;span&gt;[3]&lt;/span&gt;&lt;/span&gt;. The prevalence of ADHD in children with Intellectual Disability is 39%, with higher figures in syndromic conditions such as fragile X &lt;span&gt;&lt;span&gt;[4]&lt;/span&gt;&lt;/span&gt;. Externalizing disorders such as oppositional defiant disorder (ODD) and conduct disorder (CD) associated with ADHD strongly influence psychosocial functioning and prognosis. Oppositional defiant disorder (ODD) is frequent in children and adolescents with ADHD, about 40 to 60% in clinical samples and 20 to 30% in the general population. Internalizing and stress-related disorders are also frequent in persons with ADHD at different ages. The presence of ADHD increases the risk of being exposed to accidents and other potentially traumatising life events. ADHD is a risk factor for post-traumatic stress disorder, with rates four times higher compared with controls &lt;span&gt;&lt;span&gt;[5]&lt;/span&gt;&lt;/span&gt;. Anxiety disorders can begin at a young age with separation anxiety disorder or generalised anxiety disorder and affect about 50% adults with ADHD &lt;span&gt;&lt;span&gt;[6]&lt;/span&gt;&lt;/span&gt;. In adults with ADHD, depressive disorders are 3 to 5 times more likely than in controls &lt;span&gt;&lt;span&gt;[7]&lt;/span&gt;&lt;/span&gt;. The association between a mood disorder and impulsivity increases the risk of suicidal behaviours &lt;span&gt;&lt;span&gt;[8]&lt;/span&gt;&lt;/span&gt;. Bipolar disorder is found in 15% of adults with ADHD and is likely to be associated ","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 242-248"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pas si paradoxal … Neurobiologie du trouble déficit de l’attention–hyperactivité (TDAH) et mode d’action thérapeutique des psychostimulants","authors":"Benjamin Rolland ,&nbsp;Luc Zimmer ,&nbsp;Hugo Prunier ,&nbsp;Guillaume Sescousse","doi":"10.1016/j.amp.2024.09.002","DOIUrl":"10.1016/j.amp.2024.09.002","url":null,"abstract":"<div><h3>Background</h3><div>Attention deficit hyperactivity disorder (ADHD) is characterized by impairments in attention and executive functions, potentially associated with hyperactivity and impulsivity. Psychostimulants, which have a dopaminergic action, are the main pharmacological class of drugs used to treat ADHD, both in adults and children. However, psychostimulant intoxication is known to cause attentional problems and psychomotor agitation. It may therefore seem paradoxical to treat ADHD symptoms with molecules whose use may cause the same type of symptoms.</div></div><div><h3>Methods</h3><div>In this narrative review, based on a selection of scientific articles, we aim to highlight how recent neurobiological data, addressing the dopaminergic mechanisms of attentional and executive functions, the dopaminergic abnormalities found in ADHD, as well as the pharmacological mode of action of psychostimulants, converge to explain this apparent paradox.</div></div><div><h3>Results</h3><div>For some fifteen years now, it has been suggested that there is an “inverted U-shape” relationship between dopamine levels in the prefrontal cortex (PFC) on the one hand, and attentional and executive performances on the other hand. Both too much and too little dopamine lead to the same result, i.e. disrupted executive functions and reduced cognitive performance. In ADHD, studies show that there is an abnormally low level of dopamine in the PFC, providing a potential explanation for ADHD symptomatology. Psychostimulants act primarily by blocking the presynaptic transporters of catecholamines (i.e., dopamine and noradrenaline). Thus, by raising dopamine levels in the CPF of subjects with ADHD, they bring them back to a range that supports adequate cognitive performance, whereas in subjects without ADHD, Psychostimulants are more likely to bring dopamine concentrations to high levels, where executive functions are also suboptimal.</div></div><div><h3>Conclusions</h3><div>The “inverted U-shape” model of the relationship between dopamine levels and attentional and executive performances elegantly resolves the apparent paradox of psychostimulant efficacy in ADHD, and helps explain a number of clinical situations frequently met in this disorder. It is important to educate patients, caregivers, as well as the media and the lay public, about these neurobiological explanations, especially to combat the frequent misrepresentations associated with the use of psychostimulants in ADHD.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 323-327"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risques du méthylphénidate au long cours","authors":"Lucie Jurek ,&nbsp;Samuele Cortese ,&nbsp;Mikail Nourredine","doi":"10.1016/j.amp.2024.08.027","DOIUrl":"10.1016/j.amp.2024.08.027","url":null,"abstract":"&lt;div&gt;&lt;div&gt;The increasing administrative prevalence of Attention-Deficit Hyperactivity Disorder (ADHD) over recent years has correspondingly escalated the prescriptions of pharmacological treatments for ADHD, particularly methylphenidate (MPH), which remains the most extensively prescribed medication for this condition. In light of this trend, evaluating the long-term risks associated with using MPH is important. This article aims to present findings from studies concerning the long-term use of MPH, derived from a literature review of the past decade, primarily focusing on data sourced from PubMed to assess these risks. Our review has drawn on a diverse range of studies, including cohort studies, meta-analyses, and database reviews from various global regions, reflecting a comprehensive international perspective on the long-term safety of MPH. Our review highlights several key aspects. Initial worries about the adverse psychiatric effects of MPH did not find strong support in subsequent studies. Rather, the current body of literature suggests that MPH may have a protective effect against depression and substance use disorders. We found no significant increase in the likelihood of suicide or psychotic disorders among long-term users of MPH. In fact, studies indicate that MPH treatment might reduce the incidence of depression. Moreover, contrary to concerns that stimulant treatment might predispose individuals to SUDs, recent longitudinal studies have generally shown no increased risk of substance misuse. Some studies have even suggested a lower incidence of substance misuse among patients treated with MPH. The review also delved into cardiovascular risks, which have been a notable concern with long-term MPH usage. While short-term studies typically showed minimal cardiovascular risks, results on longer-term effects suggest potential increases in hypertension and other arterial diseases for a higher dosage, highlighting the necessity for careful cardiovascular monitoring in patients undergoing long-term treatment. No elevated risk was described concerning other cardiovascular diseases. Results regarding the impact on growth have been mixed. Some studies suggest a temporary reduction in growth velocity that normalizes over time. This pattern suggests a delayed, rather than permanently stunted, growth trajectory in children treated with MPH over the long term. Lastly, our review did not find any risk of testicular dysfunction in patients treated with MPH. The collective findings from the reviewed studies offer reassurance regarding several of the initial concerns about the long-term use of MPH. While there are concerns about potential hypertension and arterial disease risks and uncertainties regarding growth, it is important to regularly monitoring for patients using MPH. These findings should be communicated transparently to patients and their families, helping to inform shared decision-making about the initiation and continuation of MPH therapy for ","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 332-337"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TDAH : quels sont les effets cardiovasculaires du méthylphénidate et quelles sont les conséquences éventuelles pour la pratique clinique ?","authors":"Antoine Faure ,&nbsp;Laurence Bonelli ,&nbsp;Mélanie Guagenti","doi":"10.1016/j.amp.2024.08.021","DOIUrl":"10.1016/j.amp.2024.08.021","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Context&lt;/h3&gt;&lt;div&gt;Methylphenidate is the first-line pharmacological treatment for ADHD, and its prevalence continues to grow, with an increase of 116% over the last ten years in France. Its use in hospitals has been extended to neurologists, psychiatrists and pediatricians, and its prescription can be renewed by a general practitioner. Cardiovascular complications are rare, but life-threatening. Management practices currently vary widely from one medical center or doctor to another.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;Reviewing the cardiovascular effects of methylphenidate in adults and children with ADHD, aiming to propose a practical management plan without intending to replace existing recommendations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The subject under study aimed to answer the following PICO question “What are the cardiovascular consequences (outcomes) when using MPH (intervention) for an ADHD population (population) regardless of age”. We carried out systematic review of international reviews and meta-analyses, selected using the PRISMA methodology via the PubMed, Cochrane Library and Google Scholar databases. Their methodological quality was assessed using the AMSTAR-2 scale. Cardiovascular events considered were the adrenergic effects of MPH on the cardiovascular system, looking for changes in blood pressure and heart rate, and the serious cardiovascular effects represented by sudden death/arrhythmia, myocardial infarction and stroke. A total of 17 systematic reviews and meta-analyses met the eligibility criteria.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Of the 734 articles found, twelve were finally selected. Four concerned a population of children, five a mixed population of adults and children and three a population of adults only. They included two systematic reviews and ten meta-analyses. Three reviews included cohort studies and nine included randomized controlled trials. Three clinical situations can be distinguished depending on the age of the patient and the length of exposure to methylphenidate. The first, on initiation of treatment, there was a marked by a short-term increase in blood pressure and heart rate. The second involves a patient under the age of 35 with short- to medium-term exposure to MPH. A persistent adrenergic effect tends to increase the risk of sudden death by 12% (if the resting heart rate increases by ten beats per minute). This risk is further increased if the patient has psychiatric comorbidities and their associated treatments, congenital heart disease and uses recreational substances. Finally, the last situation involves a patient exposed to MPH for several years and aged over 35, whose main risk is the onset of atheromatous disease with myocardial infarction and ventricular arrhythmia. In this case, a comprehensive approach is required, identifying risk factors and behavioral factors likely to exacerbate the risk of CV disease.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The short-term cardiovasc","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 338-345"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between pediatric extremity fractures and attention deficit hyperactivity disorder","authors":"Merve Yazıcı ,&nbsp;Rıfat Şahin ,&nbsp;Mehmet Sabri Balık ,&nbsp;Ahmet Tunahan Yılmaz","doi":"10.1016/j.amp.2024.09.005","DOIUrl":"10.1016/j.amp.2024.09.005","url":null,"abstract":"<div><h3>Context</h3><div>Attention deficit hyperactivity disorder is one of the most common mental disorders of childhood, characterized by inattention, hyperactivity, and impulsive behaviors. Fractures are a common cause of hospitalization, especially in children. Recognizing fracture risk factors can aid in injury prevention and provide information for determining the appropriate interventions.</div></div><div><h3>Objectives</h3><div>This study examined whether a diagnosis of fracture is associated with the diagnosis and symptoms of attention deficit hyperactivity disorder, as well as with symptoms of oppositional defiant disorder, conduct disorder and sluggish cognitive tempo.</div></div><div><h3>Materials and methods</h3><div>The study groups consisted of children with and without extremity fractures who applied to the orthopedics and traumatology outpatient clinic. A semi-structured interview was conducted by a child psychiatrist and the scales were applied. The results obtained were compared and analyzed between patient and control groups. In addition, in patient group, fracture-related characteristics were detailed and their relationship with attention deficit hyperactivity disorder was invastigated.</div></div><div><h3>Results</h3><div>A total of 200 children and adolescents, 65 males and 35 females diagnosed with fractures, and 56 males and 46 females in the control group, were included. The mean ages of the patient with fractures and control groups were 11.74<!--> <!-->±<!--> <!-->3.40 and 11.46<!--> <!-->±<!--> <!-->3.66, respectively. Results showed that the symptoms of inattention and hyperactivity were associated with the risk of fracture. However, there was no relationship between with symptoms of other diseases and fracture.</div></div><div><h3>Conclusions</h3><div>This study is important in terms of revealing the possible relationship between attention deficit hyperactivity disorder and fracture. Questioning the symptoms of attention deficit hyperactivity disorder by surgeons and identifying children at-risk will contribute to the early diagnosis and treatment of attention deficit hyperactivity disorder.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 265-271"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostiquer et traiter le TDAH et le trouble bipolaire comorbide chez l’adulte","authors":"Sara Cipriano Salvador Marques ,&nbsp;Clément Donde ,&nbsp;Antoine Bertrand ,&nbsp;Mircea Polosan ,&nbsp;Arnaud Pouchon","doi":"10.1016/j.amp.2024.08.025","DOIUrl":"10.1016/j.amp.2024.08.025","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;Attention deficit with or without hyperactivity disorder (ADHD) and bipolar disorder (BD) are two frequent adult psychiatric conditions with high rates of comorbidity. The existence of a symptom overlaps and the lack of knowledge of physicians concerning this double diagnosis can lead to underdiagnosis or to overdiagnosis of this comorbidity, which has a therapeutic and prognostic impact. The aim of this paper is to provide the information on how to screen, diagnose, and manage this comorbidity to the French-speaking practitioners.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We conducted a narrative review of literature to gather the updated information on how to differentiate between ADHD and BD, the specificities of the comorbidity, the existing screening and diagnostic tools, and the treatment approaches.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;During the clinical interview the practitioner needs to gather information regarding the age of symptoms onset, their evolution, and analyze in detail the signs and symptoms presented. Symptoms of ADHD are often present before 7 years old which is an age where BD is rare, and BD has a cyclical evolution, as opposed to ADHD which is a chronic condition. The symptomatic dimensions that overlap between ADHD and BD can be distinguished by an in-depth analysis. Depressive episodes, periods of libido increase and/or a reduced need for sleep, psychotic symptoms, and suicidal risk are in favor of BD and they are never present in ADHD. Regarding the comorbidity of ADHD and BD, many studies are in favor of a distinct entity with a separate clinical phenotype. This clinical phenotype is often marked by the early onset of mood episodes, a high frequency of mood episodes with mixed features, a BD that is partially resistant to pharmacological treatment, a history of violent behavior and suicide attempts, the presence of certain additional comorbidities, difficulties in socio-professional settings or a history of school difficulties. These characteristics can be considered as “red flags” that the practitioner should look out for. To correctly diagnose ADHD and BD comorbidity in adults, the practitioner must do a clinical assessment where he can use psychometric tools to support his clinical observation. The screening tools that can be used for BD are the Mood Disorder Questionnaire (MDQ) and the Hypomania CheckList (HCL-32). For ADHD there is the Adult ADHD Self-Report Scale (ASRS) and the Wender Utah Rating Scale (WURS). The use of a structured clinical interview such as the Mini International Neuropsychiatric Interview (MINI) or the Diagnostic Interview for ADHD in Adults (DIVA-5) can help to diagnose the conditions. Most of these tools are validated in French. The interest of neuropsychological testing in the screening and diagnosis of this comorbidity is limited, but it can be helpful in establishing a cognitive remediation treatment plan. The treatment of ADHD and BD comorbidity includes pharm","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 282-291"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TDAH en France : la place des associations de patients et familles","authors":"Christine Gétin,&nbsp;Claudine Casavecchia","doi":"10.1016/j.amp.2024.08.028","DOIUrl":"10.1016/j.amp.2024.08.028","url":null,"abstract":"<div><div>The patient association HyperSupers TDAH France, founded in 2002 and recognized as a public utility, plays a crucial role in supporting individuals with ADHD and their families. It provides personalized support, responding to over 11,000 requests in 2023, and educates the public through its vastly visited website. HyperSupers TDAH France also holds significant advocacy power. It has contributed to the development of the recommendations by the Haute Autorité de Santé – HAS – (French National Authority for Health) and actively participates in various health institutions to influence health policies. The association works in research, education, employment, and law to ensure recognition of ADHD and support for affected individuals. Collaborating with healthcare professionals and researchers, HyperSupers fosters a better understanding of ADHD and its management. It is actively involved in the national strategy on neurodevelopmental disorders (NDD). The association's main requests include establishing an ADHD research cohort, improving professional training, ensuring early diagnosis and interventions, and taking actions to enhance the academic and professional lives of individuals with ADHD. HyperSupers also advocates for changes in university curricula and for better consideration of the specific needs of individuals with ADHD in public policies.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 231-233"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial board + Ours","authors":"","doi":"10.1016/S0003-4487(25)00061-7","DOIUrl":"10.1016/S0003-4487(25)00061-7","url":null,"abstract":"","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Page ii"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infirmiers de pratique avancée dans le TDAH : l’exemple bastiais","authors":"Mélanie Guagenti,&nbsp;Laurence Bonelli","doi":"10.1016/j.amp.2024.09.020","DOIUrl":"10.1016/j.amp.2024.09.020","url":null,"abstract":"<div><h3>Background</h3><div>The profession of Advanced Practice Nurse (APN) has been rolling out since 2018 in France with the aim of improving access to care. In Corsica until 2021, there was no specialized structure for the identification and care of adults to ensure continuity of the care pathway for children diagnosed with ADHD who became adults, or to catch up with adults not diagnosed in childhood.</div></div><div><h3>Discussion</h3><div>The creation of an ADHD referral unit at the Bastia hospital was set up to guarantee equal access to care and prevent disruption of care in adulthood by offering a multiprofessional consultation. It received funding from the Fonds d’Innovation Organisationnel en Psychiatrie in December 2022. The establishment of this unit is based on collaboration, via an organizational protocol, between a psychiatrist and an APN specializing in Psychiatry and Mental Health (PMH), enabling the creation of an innovative care pathway. The main mission is to assess and treat ADHD, to confirm the diagnosis, assess the severity of disorders and comorbidities, and propose a personalized care plan. In terms of assessment, the IPA can carry out the first full clinical interview, analyze psychometric self-evaluation scales and administer the DIVA scale. The aim of this first interview is to take a very detailed history, and a biography going back to the perinatal period, early childhood, schooling, social/emotional life, and working life, as well as researching current repercussions. In terms of care, the IPA is responsible for referring patients requiring referral therapy to the cardiologist. After initiation of treatment by the psychiatrist, the IPA alternates with the physician to conduct follow-up clinical interviews. The aim of these follow-up consultations is to assess clinical condition and treatment efficacy, detect any side effects, monitor cardiovascular parameters and renew methylphenidate treatment. In addition to their clinical skills, the IPA also plays a coordinating role in the care of adults with ADHD. Their expertise in the field of psychiatry enables them to identify and optimize treatment in cases of dual pathologies. Their knowledge of the field and the network helps to create a city-hospital network, and to ensure the fluidity of a care pathway organized in collaboration with all the players involved. The IPA also brings added value to psycho-education initiatives, whether individual or group-based. In addition, the IPA can exercise clinical leadership by raising awareness of ADHD among student nurses and IDE colleagues. Finally, the IPA can become involved in clinical research on adult ADHD.</div></div><div><h3>Synthesis</h3><div>The Bastia experiment, which can easily be replicated, confirms that APN PMHs are innovative and valuable resources whose skills bring added value to the care of adults with ADHD.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 308-311"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}